CRSP
Crispr Therapeutics AG
NASDAQ: CRSP · HEALTHCARE · BIOTECHNOLOGY
$54.11
+5.13% today
Updated 2026-10-28
Market cap
$4.76B
P/E ratio
—
P/S ratio
355.59x
EPS (TTM)
$-4.74
Dividend yield
—
52W range
$44 – $75
Volume
1.6M
Crispr Therapeutics AG (CRSP) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$54.11
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$77.26
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.9B | $0.0B | $0.4B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.